Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis (NCT04102371) | Clinical Trial Compass
CompletedPhase 3
Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis
United States9,041 participantsStarted 2020-08-25
Plain-language summary
The objectives of this multicenter pragmatic clinical trial are to compare the effectiveness and relative safety of balanced fluid resuscitation versus 0.9% "normal" saline in children with septic shock, including whether balanced fluid resuscitation can reduce progression of kidney injury.
Who can participate
Age range2 Months – 17 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Males or females age \>2 months to \<18 years
✓. Clinician concern for septic shock, operationalized as:
✓. a "positive" ED sepsis alert confirmed by a physician OR
✓. physician decision to treat for septic shock OR
✓. a physician diagnosis of septic shock requiring parenteral antibiotics and fluid resuscitation
✓. Administration of at least one IV/Intraosseous (IO) fluid bolus for resuscitation and additional fluid deemed likely to be necessary to treat poor perfusion, or clinician judgment that \>1 fluid bolus is highly likely to be required. Poor perfusion is defined as physician's judgement of hypotension or abnormal (either "flash" or "prolonged") capillary refill.
✓. Receipt of ≤40 mL/kg IV/IO total crystalloid fluid prior to randomization
✓. Parental/guardian permission (informed consent) if time permits; otherwise, Exception from informed consent (EFIC) criteria met
Exclusion criteria
✕. Treating physician judges that patient's condition deems it unsafe to administer either NS or BF (since patients will be equally likely to receive NS or BF at time of study enrollment), including:
✕. Clinical suspicion for impending brain herniation
✕. Known hyperkalemia, defined as non-hemolyzed whole blood or plasma/serum potassium \> 6 mEq/L, based on data available at or before patient meets criteria for study enrollment
What they're measuring
1
Proportion of participants with Major Adverse Kidney Events within 30 days (MAKE30)
Timeframe: Between randomization and 30 days post enrollment, discharge or death, whichever comes first.
✕. Known hypercalcemia, defined as plasma/serum total calcium \>12 mg/dL or whole blood ionized calcium \>1.35 mmol/L, based on data available at or before patient meets criteria for study enrollment
✕. Known acute fulminant hepatic failure, defined as plasma/serum alanine aminotransferase (ALT) \>10,000 U/L or total bilirubin \>12.0 mg/dL, based on data available at or before patient meets criteria for study enrollment
✕. Known history of severe hepatic impairment, defined as cirrhosis, "liver failure", or awaiting transplant
✕. Known history of severe renal impairment, defined as peritoneal dialysis or hemodialysis
✕. Known metabolic/mitochondrial disorder, inborn error of metabolism, or primary mineralocorticoid deficiency as reported by participant, legally authorized representative (LAR) or accompanying caregiver, or as listed in the medical record